Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-09-14), Guard Therapeutics International AB's 3-1 Month Momentum % is 18.34%.
OSTO:GUARD's 3-1 Month Momentum % is ranked better than 74.87% of 1377
companies
in the Biotechnology industry
Industry Median: 1.49
vs OSTO:GUARD: 18.34
Guard Therapeutics International AB (OSTO:GUARD) 3-1 Month Momentum % Explanation
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Guard Therapeutics International AB 3-1 Month Momentum % Related Terms
OSTO:GUARD vs VRTX, REGN, MRNA: 3-1 Month Momentum % Comparison
For the Biotechnology subindustry, Guard Therapeutics International AB's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Guard Therapeutics International AB 3-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Guard Therapeutics International AB's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Guard Therapeutics International AB's 3-1 Month Momentum % falls into.
Guard Therapeutics International AB (OSTO:GUARD) 3-1 Month Momentum % Calculation
3-1 Month Momentum % is calculated as following:
3-1 Month Momentum %
=
( Price 1-month ago
/
Price 3-month ago
- 1 )
*
100 %
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Guard Therapeutics International AB (OSTO:GUARD) has a 3-1 Month Momentum % of 18.34% as of Sep. 14, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Guard Therapeutics International AB and its competitors. According to the industry distribution chart, Guard Therapeutics International AB ranks #346 out of 1377 companies in the Biotechnology industry, placing it in the top 25.1%.
Is Guard Therapeutics International AB's 3-1 Month Momentum % too high?
Guard Therapeutics International AB's current 3-1 Month Momentum % is 18.34%. The Biotechnology industry median 3-1 Month Momentum % is 1.49. Guard Therapeutics International AB's value of 18.34% is 1130.9% above this industry median. Based on the distribution chart, Guard Therapeutics International AB ranks #346 out of 1377 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Guard Therapeutics International AB has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Guard Therapeutics International AB's 3-1 Month Momentum % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Guard Therapeutics International AB ranks #346 out of 1377 companies for 3-1 Month Momentum %. This puts Guard Therapeutics International AB in the upper half of its industry. The industry median 3-1 Month Momentum % is 1.49. Guard Therapeutics International AB's value of 18.34% is 1130.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
The median 3-1 Month Momentum % among Biotechnology companies is 1.49, based on 1,377 companies in the industry. Companies in the top quartile (top 25%) have a 3-1 Month Momentum % significantly above this median, while those in the bottom quartile fall well below. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Guard Therapeutics International AB's current 3-1 Month Momentum % of 18.34% is 1130.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Guard Therapeutics International AB and its competitors. For the Biotechnology industry, the median 3-1 Month Momentum % is 1.49 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Guard Therapeutics International AB's current 3-1 Month Momentum % is 18.34%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Guard Therapeutics International AB stock overvalued right now?
Guard Therapeutics International AB (OSTO:GUARD) has a current 3-1 Month Momentum % of 18.34%. The current 3-1 Month Momentum % is 18.34% and 1130.9% above the Biotechnology industry median of 1.49. Guard Therapeutics International AB's overall GF Score™ is 23/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Guard Therapeutics International AB (OSTO:GUARD), the current 3-1 Month Momentum % is 18.34% as of Sep. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Guard Therapeutics International AB is engaged in developing and commercializing the lead drug candidate ROSgard, and thereby contribute to the better and less harmful treatment of acute kidney injuries.
23GF Score
Get the complete analysis for OSTO:GUARD
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:GUARD has been successfully added to your 
